NCT07211958
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07211958
Title Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation (REVEAL-ND NPM1)
Acronym REVEAL-ND NPM1
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Syndax Pharmaceuticals
Indications
Therapies
Age Groups: child | adult | senior
Covered Countries ISR


No variant requirements are available.